PsyBio Therapeutics Further Expands Testing of Portfolio Compounds
OXFORD, Ohio and COCONUT CREEK, Fla., May 6, 2022 /CNW/ – PsyBio Therapeutics Corp. (TSXV: PSYB) (OTCQB: PSYBF) (“PsyBio” or the “Company“), a fully integrated and intellectual property driven biotechnology company developing novel, bespoke psychoactive medicinal candidates targeting the potential treatment of mental health…